Pain in oxaliplatin-induced neuropathy - Sensitisation in the peripheral and central nociceptive system

European Journal of Cancer

Volumn 43, Issue 18, 2007, Pages 2658-2663

  Binder, Andreas ^a,b   Stengel, Maike ^a,b   Maag, Rainer ^a,b   Wasner, Gunnar ^a,b   Schoch, Robert ^b   Moosig, Frank ^b   Schommer, Bernhard ^c   Baron, Ralf ^a,b  

^a Division of Neurological Pain Research and Therapy   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c University Teaching Hospital Rendsburg   (Germany)

Author keywords

Cold; Neuropathy; Oxaliplatin; Pain; Quantitative sensory testing (QST); Sensitisation

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; HYPERALGESIA; HYPESTHESIA; MALE; NEUROPATHIC PAIN; NOCICEPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYMPTOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; NEURALGIA; NOCICEPTORS; ORGANOPLATINUM COMPOUNDS; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 36348997574     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.030     Document Type: Article

References (30)

1. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 350 (2004) 2343-2351
2. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
3. Cassidy J., and Misset J.L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29 (2002) 11-20
4. Extra J.M., Marty M., Brienza S., and Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25 (1998) 13-22
5. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39 (2005) 128-135
6. Culy C.R., Clemett D., and Wiseman L.R. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60 (2000) 895-924
7. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., and Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406 (2000) 25-32
8. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., and Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 (2001) 2293-2297
9. Webster R.G., Brain K.L., Wilson R.H., Grem J.L., and Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146 (2005) 1027-1039
10. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., and Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 (2002) 1767-1774
11. Holmes J., Stanko J., Varchenko M., et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46 (1998) 342-351
12. Cavaletti G., Tredici G., Petruccioli M.G., et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37 (2001) 2457-2463
13. Jamieson S.M., Liu J., Connor B., and McKeage M.J. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56 (2005) 391-399
14. Lecomte T., Landi B., Beaune P., Laurent-Puig P., and Loriot M.A. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12 (2006) 3050-3056
15. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 (2002) 9-17
16. Rolke R., Baron R., Maier C., et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standarized protocol and reference values. Pain 125 (2006) 231-243
17. Baron R. Mechanisms of disease: neuropathic pain - a clinical perspective. Nat Clin Pract Neurol 2 (2006) 95-106
18. Stein C., and Mendl G. The German counterpart to McGill Pain Questionnaire. Pain 32 (1988) 251-255
19. Leonard G.D., Wright M.A., Quinn M.G., et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5 (2005) 116
20. Ling B., Authier N., Balayssac D., Eschalier A., and Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128 (2006) 225-234
21. Krishnan A.V., Goldstein D., Friedlander M., and Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32 (2005) 51-60
22. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., and Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 (2004) 387-392
23. Durand J.P., Alexandre J., Guillevin L., and Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 16 (2005) 587-591
24. von Delius S., Eckel F., Wagenpfeil S., et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 25 (2007) 173-180
25. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., and Sindrup S.H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118 (2005) 289-305
26. Wasner G., Schattschneider J., Binder A., and Baron R. Topical menthol - a human model for cold pain by activation and sensitization of C nociceptors. Brain 27 (2004) 1159-1171
27. Tominaga M., and Caterina M.J. Thermosensation and pain. J Neurobiol 61 (2004) 3-12
28. Waxman S.G., and Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med 11 (2005) 555-562
29. Cox J.J., Reimann F., Nicholas A.K., et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444 (2006) 894-898
30. Kim H., Mittal D.P., Iadarola M.J., and Dionne R.A. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J Med Genet 43 (2006) e40